Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 11:58AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own0.40% Shs Outstand7.92M Perf Week23.69%
Market Cap28.12M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float7.89M Perf Month13.06%
Income-9.95M PEG- EPS next Q- Inst Own2.28% Short Float0.09% Perf Quarter222.73%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.29 Perf Half Y17.36%
Book/sh-0.44 P/B- EPS next Y- ROA- Short Interest0.01M Perf Year-1.39%
Cash/sh0.17 P/C21.46 EPS next 5Y- ROE- 52W Range1.08 - 5.50 Perf YTD13.78%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-35.45% Beta0.94
Dividend TTM- Quick Ratio0.44 Sales past 5Y0.00% Gross Margin- 52W Low229.47% ATR (14)0.39
Dividend Ex-Date- Current Ratio0.44 EPS Y/Y TTM13.28% Oper. Margin0.00% RSI (14)63.36 Volatility12.72% 16.66%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price80.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q100.00% Payout- Rel Volume0.81 Prev Close3.53
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 16 BMO Avg Volume25.51K Price3.55
SMA2015.34% SMA5055.29% SMA20036.81% Trades Volume8,589 Change0.55%
Date Action Analyst Rating Change Price Target Change
Jan-04-19Upgrade B. Riley FBR Neutral → Buy $2.50 → $3
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3
Sep-22-17Upgrade William Blair Mkt Perform → Outperform
May-31-17Upgrade Chardan Capital Markets Sell → Neutral $6
Apr-17-17Reiterated Chardan Capital Markets Sell $6.50 → $5
Jul-11-16Initiated Chardan Capital Markets Sell $5
Jun-05-24 08:00AM
Jun-04-24 08:00AM
May-16-24 08:00AM
May-01-24 08:01AM
08:00AM Loading…
Apr-15-24 08:00AM
Apr-01-24 06:30AM
Mar-08-24 04:38PM
Mar-05-24 08:00AM
Jan-02-24 08:00AM
Dec-14-23 08:00AM
Dec-01-23 08:00AM
Nov-16-23 08:00AM
Nov-06-23 08:00AM
Oct-04-23 07:00AM
07:00AM Loading…
Oct-03-23 07:00AM
Sep-29-23 08:00AM
Sep-27-23 08:00AM
Sep-21-23 08:00AM
Sep-19-23 08:00AM
Sep-05-23 08:00AM
Aug-21-23 02:01PM
Aug-18-23 08:00AM
Aug-15-23 08:00AM
Aug-02-23 08:00AM
Aug-01-23 07:30AM
Jul-27-23 08:00AM
Jul-19-23 08:00AM
Jul-13-23 08:00AM
Jul-11-23 08:00AM
08:00AM Loading…
Jul-06-23 08:00AM
Jul-05-23 08:00AM
May-16-23 04:05PM
May-01-23 08:00AM
Apr-25-23 04:15PM
Apr-19-23 02:01PM
Apr-14-23 08:00AM
Apr-11-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 09:09AM
Mar-29-23 08:00AM
Feb-21-23 08:00AM
Feb-15-23 08:00AM
Feb-13-23 08:00AM
Jan-04-23 08:00AM
Dec-01-22 08:00AM
Nov-22-22 08:00AM
Nov-10-22 08:00AM
Nov-09-22 08:00AM
Nov-08-22 03:40PM
Oct-31-22 08:00AM
Oct-28-22 04:30PM
Sep-27-22 08:00AM
Sep-22-22 08:00AM
Sep-12-22 08:00AM
Sep-08-22 06:48AM
Aug-01-22 08:00AM
Jul-29-22 09:36AM
Jul-28-22 08:00AM
Jul-20-22 06:00AM
Jul-07-22 08:00AM
Jun-13-22 07:00AM
May-19-22 04:05PM
May-16-22 06:00AM
May-11-22 07:00AM
May-10-22 07:00AM
May-09-22 07:00AM
Mar-21-22 08:00AM
Mar-09-22 07:30AM
Mar-08-22 11:45AM
Mar-05-22 07:02AM
Mar-02-22 07:00AM
Feb-28-22 09:12AM
Feb-11-22 07:00AM
Jan-26-22 08:30AM
Jan-19-22 08:30AM
Jan-04-22 07:00AM
Dec-30-21 11:03AM
Dec-05-21 06:13AM
Dec-03-21 07:45AM
Dec-01-21 08:30AM
Oct-26-21 08:00AM
Oct-25-21 08:30AM
Sep-22-21 09:00AM
Sep-10-21 08:30AM
Sep-07-21 07:00AM
Jul-07-21 09:15AM
Jun-29-21 04:01PM
Apr-28-21 10:25AM
Apr-22-21 07:30AM
Apr-20-21 06:40PM
Apr-12-21 12:48PM
Mar-04-21 08:30AM
Feb-25-21 01:41PM
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.